Published in J Cardiovasc Pharmacol on February 01, 1990
Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol (2008) 0.99
Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol (1991) 0.93
Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol (2008) 0.90
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. PLoS One (2013) 0.82
ACE inhibitors for heart failure: a question of dose. Br Heart J (1994) 0.81
Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker. Heart Vessels (2011) 0.77
Role of aliskiren in blood pressure control and renoprotection. Int J Nephrol Renovasc Dis (2011) 0.77
Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis. Clin Exp Nephrol (2012) 0.76
Beta adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics. Heart (1998) 0.75
Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med (1978) 5.04
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ (2001) 4.66
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens (1994) 2.91
A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet (1977) 2.90
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation (2000) 2.71
Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol (1982) 2.49
Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. J Cardiovasc Pharmacol (1987) 2.36
Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med (1979) 2.31
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med (1972) 2.10
Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology (1993) 2.10
Vitamin D levels and associated factors: a population-based study in Switzerland. Swiss Med Wkly (2012) 2.07
European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens (2010) 2.06
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health (2004) 2.00
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet (1981) 1.99
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol (1982) 1.95
Improvement of chronic congestive heart-failure by oral captopril. Lancet (1979) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol (1998) 1.92
Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol (1981) 1.88
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens (2001) 1.87
Knowledge, attitudes, and practices on hypertension in a country in epidemiological transition. Hypertension (1998) 1.87
Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med (1998) 1.83
An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med (1974) 1.82
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension (1980) 1.81
Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens (2001) 1.80
Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet (1973) 1.78
Endothelial function in chronic congestive heart failure. Am J Cardiol (1992) 1.69
Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord (2002) 1.69
Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension (1992) 1.64
Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol (1987) 1.56
Fatal pancytopenia associated with the use of captopril. Ann Intern Med (1981) 1.54
Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol (1983) 1.54
Clinically suspected primary acquired nasolacrimal duct obstruction: clinicopathologic review of 150 patients. Ophthalmology (1997) 1.51
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest (1970) 1.42
[Managing hypertension: the uncertainty of definitions and targets]. Rev Med Suisse (2010) 1.41
Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock (2001) 1.41
Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest (2001) 1.41
Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension (1997) 1.41
[Antihypertensive agents used as first line agents: beta-blockers under pressure]. Rev Med Suisse (2006) 1.39
A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism. Proc Natl Acad Sci U S A (1997) 1.37
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol (1987) 1.37
Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta-subunit of the amiloride-sensitive epithelial sodium channel. Proc Natl Acad Sci U S A (1999) 1.33
A mouse model for Liddle's syndrome. J Am Soc Nephrol (1999) 1.30
Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation (1978) 1.30
Angiotensin II, vasopressin, and sympathetic activity in conscious rats with endotoxemia. Am J Physiol (1985) 1.29
Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am J Ophthalmol (1988) 1.29
Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country. J Hum Hypertens (2006) 1.27
Vasopeptidase inhibition and angio-oedema. Lancet (2000) 1.27
Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res (1975) 1.27
Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension (1998) 1.25
Synergistic effects of fluid shear stress and cyclic circumferential stretch on vascular endothelial cell morphology and cytoskeleton. Arterioscler Thromb Vasc Biol (1995) 1.25
Calcineurin blockade prevents cardiac mitogen-activated protein kinase activation and hypertrophy in renovascular hypertension. J Biol Chem (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure. Lancet (1978) 1.23
Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension. J Clin Invest (1972) 1.21
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther (1999) 1.20
Short time exposure to lipopolysaccharide is sufficient to activate human monocytes. J Immunol (1993) 1.20
Compliance with antihypertensive treatment: implications for practice. Blood Press (1997) 1.19
Hypertension of renal origin: evidence for two different mechanisms. Science (1971) 1.16
Proximal sodium reabsorption: An independent determinant of blood pressure response to salt. Hypertension (2000) 1.16
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone (1996) 1.14
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest (2001) 1.13
Need for beta-blockade in hypertension reduced with long-term minoxidil. Br Med J (1978) 1.12
Isolated office hypertension: a prehypertensive state? J Hypertens (1996) 1.11